simendan (Levosimendan)

01/01/2015 - "Our study showed levosimendan significantly and safely improved clinical outcomes of refractory heart failure in elderly patients."
01/01/2016 - "The updated results suggest that repetitive or intermittent levosimendan administration in advanced heart failure is associated with a significant reduction in mortality at the longest follow-up available. "
01/01/2011 - " vivo, levosimendan treatment for two hours resulted in a significant reduction of PMA stimulated oxidative burst by 45% (P < 0.01) and fMLP stimulated oxidative burst by 49% (P < 0.05) in patients with acute heart failure. "
07/01/2009 - "LIhFE and LVD36 show a significant improvement in QOL in heart failure patients after a 6-month period of monthly intermittent administration of levosimendan. "
05/01/2003 - "Preliminary results also suggest that levosimendan may be beneficial for the treatment of patients with right ventricular heart failure. "

02/01/2015 - "Clinical trials showed that levosimendan was particularly effective in HF due to myocardial infarction. "
09/01/2002 - "To evaluate the safety and efficacy of levosimendan in patients with left ventricular failure complicating acute myocardial infarction. "
05/11/2001 - "Improved survival with simendan after experimental myocardial infarction in rats."
08/18/2008 - "In previous studies, it has recently been shown that levosimendan improves the Doppler echocardiographic parameters of the left ventricular (LV) diastolic function in patients with anterior acute myocardial infarction. "
02/01/2015 - "These findings could explain, at least in part, the beneficial effects of levosimendan after myocardial infarction. "

03/22/2006 - "Levosimendan causes rapid improvement in hemodynamic function in patients with cardiogenic shock. "
12/15/2004 - "If the promising results of smaller studies (LIDO, RUSSLAN) with respect to the mortality of the treated patients can be supported by a larger, already initiated study (SURVIVE), levosimendan would be a valuable alternative and/or addition to the conventional therapy of cardiogenic shock."
08/18/2008 - "Levosimendan seems to be effective in improving the Doppler echocardiographic parameters of LV diastolic function in patients with STEMI revascularised by primary PCI who developed cardiogenic shock."
01/01/2010 - "Efficacy of levosimendan in Takotsubo-related cardiogenic shock."
12/01/2013 - "The author, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses of these papers are shown in table 1. The clinical bottom line is that there is no evidence that levosimendan improves outcome in cardiogenic shock. "

10/01/2006 - "The left ventricular developed pressure-representing the functional recovery of the heart after ischemia-that was significantly improved by levosimendan pretreatment (38 +/- 6% vs 16 +/- 5% in controls, P < 0.05). "
01/01/2015 - "Levosimendan ameliorates liver injury induced by myocardial IR, especially when administered before induction of ischemia (Fig. "
10/01/2006 - "Prior to ischemia, levosimendan improved left ventricular systolic and diastolic function with coincident preload and afterload reduction. "
08/01/2010 - "The aim of this study was to investigate the effect of levosimendan on apoptosis and infarct size when administered before ischemia in an isolated rat heart model. "
06/01/2008 - "The aim of this study was to clarify whether levosimendan could prevent lung tissue injury from limb ischemia/reperfusion. "

06/01/2014 - "These preliminary results show that timely perioperative levosimendan treatment is feasible, has a favourable safety profile safe and may help to prevent low cardiac output syndrome. "
06/01/2006 - "The efficacy of levosimendan treatment for a low cardiac output status following cardiac surgery has not been established. "
05/01/2006 - "Levosimendan was safely used in a small number of pediatric patients with established low cardiac output state who demonstrated improved hemodynamics and tissue perfusion, with a tendency to reduced conventional inotrope usage, and this warrants its evaluation as an inotrope in the pediatric population."
10/01/2013 - "In conclusion, the above studies were in favour of levosimendan as a safe and feasible drug providing potential clinical benefit in low cardiac output syndrome (LCOS) and post-cardiac surgeries when other vasoactive drugs were insufficient to maintain stable haemodynamics. "
04/01/2009 - "This study was performed to evaluate the efficacy and safety of levosimendan (LEVO) in pediatric patients with low cardiac output syndrome. "